FIELD: medicine.
SUBSTANCE: the present innovation refers to autologous T-cellular vaccine and method for its obtaining. It is necessary to obtain a lot of patient's mononuclear T-cell-containing cells followed by incubating these cells with one of antigens associated with multiple sclerosis followed by their stimulating with antigen-presenting cells and multiple sclerosis-associated antigen and repeated stimulation of T-cells with a multiple sclerosis-associated antigen, stimulation with mitogen at the presence of interleukin-2 and repetition of the stages mentioned. The vaccine mentioned could be applied for treating multiple sclerosis at decreased number of relapses in such patients.
EFFECT: higher efficiency.
19 cl, 1 dwg, 7 ex, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| RELEASE AND IDENTIFICATION OF T-CELLS | 2003 |
|
RU2327487C2 |
| METHOD FOR PRODUCTION OF POLYCLONAL T-CELL VACCINE USEFUL IN TREATMENT OF IMMUNOLOGICAL DISORDERS | 2004 |
|
RU2277422C2 |
| T-CELLULAR VACCINE FOR CEREBROSPINAL SCLEROSIS TREATMENT | 1998 |
|
RU2209633C2 |
| PEPTIDE FROM THE COMPOSITION OF THE IMMUNOGLOBULIN HUMAN HEAVY CHAIN, SUITABLE FOR TREATMENT OF MULTIPLE SCLEROSIS | 2016 |
|
RU2646817C1 |
| METHOD OF THERAPY OF REMITTENT MULTIPLE SCLEROSIS | 2012 |
|
RU2523058C2 |
| ACTH-LIKE PEPTIDE WITH IMMUNOSUPRESSOR FUNCTION | 2017 |
|
RU2681317C1 |
| LIPOSOMES CONTAINING OLIGOPEPTIDES - FRAGMENTS OF MYELIN BASIC PROTEIN, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING MULTIPLE SCLEROSIS | 2009 |
|
RU2448685C2 |
| ACTIVE DRUG INGREDIENT, DRUG, PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATMENT OF DEMYELINATING DISEASES OF LIVING ORGANISM, INCLUDING DISEASE PREVENTION | 2015 |
|
RU2631887C2 |
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR REMITTENT AND SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS | 2010 |
|
RU2428693C1 |
| COMPOSITIONS FOR TREATMENT OF DISSEMINATED SCLEROSIS | 2008 |
|
RU2492234C2 |
